FIBROTHERAPEUTICS INC
Charleston, SC · Biotech · Private
Modified peptide therapeutics derived from caveolin-1 scaffolding domain for heart failure and fibrotic disease treatment
- Grants
- $1.8M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | $299,930 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | $299,930 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease | $259,601 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | $299,972 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | $299,972 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | $6,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapeutic for Kidney Failure: A Modified, Water-Soluble Orally-Active Caveolin-1 Scaffolding Domain Peptide with Improved Characteristics for Drug Development | $337,740 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3138 | Nirogyone Therapeutics LLC | — | — |
| 3139 | SEAK Therapeutics, LLC | — | — |
| 3140 | ALCAMENA STEM CELL THERAPEUTICS, LLC | — | — |
| 3141 | FIBROTHERAPEUTICS INC | — | — |
| 3142 | MARWELL BIO INC. | — | — |
| 3143 | Iria Pharma, LLC | — | — |
| 3144 | DINYA DNA INC | — | $3.8M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.